Processing Magazine

Spectrum reaches settlement with Glaxo

November 13, 2006

Spectrum Pharmaceuticals Inc. has settled a patent dispute with GlaxoSmithKline PLC related to its generic version of Glaxo''s Imitrex injection, according to the Associated Press. Under terms of the settlement, Spectrum said it can exclusively distribute authorized generic versions of certain sumatriptan injection products in the U.S. with an expected launch during Glaxo''s sumatriptan pediatric exclusivity period which begins on Aug. 6, 2008 but with the launch occurring no later than Nov. 6, 2008. Spectrum will launch its sumatriptan injection through Par Pharmaceuticals Cos., its partner for the sale and distribution of the drug, which is used to treat migraines and cluster headache episodes.